1. Home
  2. NSIT vs ACAD Comparison

NSIT vs ACAD Comparison

Compare NSIT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insight Enterprises Inc.

NSIT

Insight Enterprises Inc.

N/A

Current Price

$170.00

Market Cap

5.1B

Sector

Technology

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$18.40

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSIT
ACAD
Founded
1988
1993
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.4B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
NSIT
ACAD
Price
$170.00
$18.40
Analyst Decision
Hold
Buy
Analyst Count
4
20
Target Price
★ $177.50
$30.53
AVG Volume (30 Days)
368.9K
★ 2.5M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.12
EPS
★ 4.28
0.51
Revenue
★ $8,247,180,000.00
$726,437,000.00
Revenue This Year
$12.22
$19.43
Revenue Next Year
$4.75
$13.21
P/E Ratio
$39.68
★ $35.70
Revenue Growth
N/A
★ 40.45
52 Week Low
$63.62
$15.86
52 Week High
$182.12
$30.96

Technical Indicators

Market Signals
Indicator
NSIT
ACAD
Relative Strength Index (RSI) 54.31 39.71
Support Level $150.96 N/A
Resistance Level $179.73 $22.72
Average True Range (ATR) 8.77 1.12
MACD -0.96 -0.08
Stochastic Oscillator 67.10 37.49

Price Performance

Historical Comparison
NSIT
ACAD

About NSIT Insight Enterprises Inc.

Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: